CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $356,019 | +89.4% | 11,971 | +14.8% | 0.00% | 0.0% |
| Q2 2023 | $187,967 | -8.5% | 10,431 | -7.0% | 0.00% | 0.0% |
| Q4 2022 | $205,363 | +0.7% | 11,222 | +8.9% | 0.00% | 0.0% |
| Q3 2022 | $204,000 | +8.5% | 10,309 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $188,000 | -36.9% | 10,079 | -25.7% | 0.00% | 0.0% |
| Q1 2022 | $298,000 | -37.4% | 13,559 | -19.1% | 0.00% | 0.0% |
| Q4 2021 | $476,000 | +73.7% | 16,755 | +28.5% | 0.00% | 0.0% |
| Q3 2021 | $274,000 | -10.5% | 13,034 | -19.6% | 0.00% | 0.0% |
| Q2 2021 | $306,000 | +70.0% | 16,217 | +37.6% | 0.00% | 0.0% |
| Q1 2021 | $180,000 | +15.4% | 11,786 | +6.4% | 0.00% | 0.0% |
| Q4 2020 | $156,000 | -24.6% | 11,075 | +21.7% | 0.00% | 0.0% |
| Q1 2019 | $207,000 | -22.2% | 9,098 | +2.4% | 0.00% | -50.0% |
| Q4 2018 | $266,000 | – | 8,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |